Science 37 is submitting the 2027 Participant Engagement Award for submissions to recognize creative, innovative work from sponsors, sites, CROs, patient organizations, agencies, start-ups, and anyone else pushing us to think differently about recruitment and retention.
Public source
Publisher name
Public post
It’s hard to believe we’re heading into the 11th year of the Scope Participant Engagement Award. When David Sall, Micah Lieberman, and I created the PEA, the idea was pr…
Company
Science 37
The First & Only FDA-Inspected Direct-to-Patient Clinical Trial Site
- Industry
- Research Services
- Location
- Morrisville, US
- Company size
- 201–500 employees
About Science 37
Science 37 is a modern clinical research site that delivers trials directly to patients’ homes. With nationwide reach and medical licensure across all 50 states, its Direct-to-Patient Site enables sponsors to expand access, improve retention, and enroll more representative patient populations compared to relying solely on a traditional site-based approach. Science 37 operates under a single Form FDA 1572 and a central IRB, supported by centralized medical oversight, research-grade nursing, and specialized direct-to-patient clinical operations. The company has successfully completed multiple FDA inspections, resulting in FDA approvals, achieving No Action Indicated (NAI) classifications with zero Form 483 observations. With more than a decade of experience, Science 37 has supported over 200 clinical trials across Phases I–IV and observational studies. Its model consistently delivers strong performance, including approximately 86% completion rates and contributing an average of 20–30% of total study enrollment as a single site. These outcomes have been validated by the Tufts Center for the Study of Drug Development (Tufts CSDD). To learn more, visit www.science37.com or email science37@science37.com.
See moreLatest activity
Latest activity from Science 37
7 signals
Presence & Recognition
Science 37 is attending the Rare Trials Summit in Boston from September 14 to 16.
Presence & Recognition
Science 37 employees Scott Arceri and Kelly McKee will attend Partnerships with Sites and DPHARMAR in Boston, MA on September 14–16 to share new insights on direct-to-patient research.
Presence & Recognition
Science 37 CEO Tyler Van Horn reflected on the decisions, assumptions, and lessons shaped by the company's work in decentralized clinical trials in a new piece published on LinkedIn.
Discover more
Similar signals
Similar public activity from other companies.
Presence & Recognition
Society for Clinical Research Sites (SCRS)
Society for Clinical Research Sites (SCRS) announced that the 2026 Eagle Award CRO finalists include IQVIA, Medpace, Novotech, Parexel, and Worldwide Clinical Trials.
Presence & Recognition
Paradigm Clinical Research
Paradigm Clinical Research CEO Kurt Mussina and VP of Operations Amy Henderson will attend the Partnerships with Sites Summit and DPHARM: Disruptive Innovations to Modernize Clinical Trials in Boston for conversations focused on collaboration and clinical research efficiency.
Presence & Recognition
Civia Health
Civia Health was named as one of three finalists for the Excellence in Patient Centricity Award at the Society for Clinical Research Sites (SCRS) Global Site Solutions Summit Awards.
Presence & Recognition
CISCRP
CISCRP representative Kimbra Edwards, PhD is attending Clinical Data Disclosure & Transparency 2026 panel discussion on Patient and Site Perspective: Bridging Communication Gaps.
Presence & Recognition
Veristat